The benefit of implementing a heart failure disease management program

Archives of Internal Medicine

Volumn 161, Issue 18, 2001, Pages 2223-2228

  Whellan, D J ^a   Gaulden, L ^a   Gattis, W A ^a   Granger, B ^a   Russell, S D ^a   Blazing, M A ^a   Cuffe, M S ^a   O'Connor, C M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH PROGRAM; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0035829092     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.18.2223     Document Type: Article

References (25)

1. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: The future rise of heart failure
2. Guidelines for the evaluation in management of heart failure: Report of American College of Cardiology/American Heart Association Task for Practice Guidelines (Committee on Evaluation of Heart Failure)
3. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: Pharmacological approaches
4. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure
5. The impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure
6. Effect of a heart failure program on hospitalization frequency and exercise tolerance
7. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: A randomised controlled study
8. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study
9. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization
10. Prevention of hospitalizations for heart failure with an interactive home monitoring program
11. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
14. Economic impact of heart failure in the United States: Time for a different approach
15. Perspective of the pharmaceutical industry on the development of new drugs for heart failure
16. Natural history and patterns of current practice in heart failure
17. Differences between primary care physicians and cardiologists in management of congestive heart failure: Relation to practice guidelines
18. Treatment of patients admitted to the hospital with congestive heart failure: Specialty-related disparities in practice patterns and outcomes
19. Contemporary management of patients with left ventricular systolic dysfunction: Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry
20. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
21. Persons with chronic conditions: Their prevalence and costs